Insider-Trading
Aktuelle Insider-Transaktionen (SEC Form 4) — Käufe und Verkäufe von Vorständen, Direktoren und Großaktionären.
| Ticker | Insider | Funktion | Datum | Transaktion | Kurs ($) | Stück | Wert ($) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| ROIV | Epperly Melissa B, | Director | 15.09.2026 | Verkauf | 40,38 | 600 | 24.228 | Form 4 |
| ROIV | Epperly Melissa B, | Director | 15.09.2026 | Verkauf | 39,65 | 4.338 | 172.002 | Form 4 |
| ROIV | Fitzgerald Meghan | Director | 15.09.2026 | Verkauf | 40,45 | 400 | 16.180 | Form 4 |
| ROIV | Fitzgerald Meghan | Director | 15.09.2026 | Verkauf | 39,68 | 4.712 | 186.972 | Form 4 |
| ROIV | Epperly Melissa B, | Director | 10.09.2026 | Steuer-Abgabe | 40,94 | 2.179 | 89.208 | Form 4 |
| ROIV | Oren Ilan | Director | 10.09.2026 | Steuer-Abgabe | 40,94 | 2.378 | 97.355 | Form 4 |
| ROIV | Fitzgerald Meghan | Director | 10.09.2026 | Steuer-Abgabe | 40,94 | 1.743 | 71.358 | Form 4 |
| ROIV | Momtazee James C | Director | 10.09.2026 | Steuer-Abgabe | 40,94 | 2.905 | 118.931 | Form 4 |
| ROIV | Gold Daniel Allen | Director | 10.09.2026 | Steuer-Abgabe | 40,94 | 5.133 | 210.145 | Form 4 |
| ROIV | Fitzgerald Meghan | Director | 08.09.2026 | Verkauf | 39,90 | 20.000 | 798.000 | Form 4 |
| ROIV | Fitzgerald Meghan | Director | 08.09.2026 | Optionsausübung | 8,80 | 20.000 | 176.000 | Form 4 |
| ROIV | Venker Eric | President & Immunovant CEO | 28.08.2026 | Verkauf | 36,44 | 33.818 | 1.232.328 | Form 4 |
| ROIV | Venker Eric | President & Immunovant CEO | 28.08.2026 | Verkauf | 35,63 | 166.182 | 5.921.065 | Form 4 |
| ROIV | Venker Eric | President & Immunovant CEO | 28.08.2026 | Optionsausübung | 3,85 | 200.000 | 770.000 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 21.08.2026 | Verkauf | 36,48 | 144.756 | 5.280.699 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 21.08.2026 | Optionsausübung | 3,85 | 144.756 | 557.311 | Form 4 |
| ROIV | Pulik Richard | CFO | 20.08.2026 | Steuer-Abgabe | 36,84 | 5.749 | 211.793 | Form 4 |
| ROIV | Venker Eric | President & Immunovant CEO | 20.08.2026 | Steuer-Abgabe | 36,84 | 13.909 | 512.408 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 20.08.2026 | Verkauf | 37,30 | 17.519 | 653.459 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 20.08.2026 | Optionsausübung | 3,85 | 17.519 | 67.448 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 19.08.2026 | Verkauf | 37,17 | 172.899 | 6.426.656 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 19.08.2026 | Optionsausübung | 3,85 | 172.899 | 665.661 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 18.08.2026 | Verkauf | 37,18 | 31.801 | 1.182.361 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 18.08.2026 | Optionsausübung | 3,85 | 31.801 | 122.434 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 18.08.2026 | Verkauf | 36,59 | 105.141 | 3.847.109 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 18.08.2026 | Optionsausübung | 3,85 | 105.141 | 404.793 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 17.08.2026 | Verkauf | 36,25 | 284.707 | 10.320.629 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 17.08.2026 | Optionsausübung | 3,85 | 284.707 | 1.096.122 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 14.08.2026 | Verkauf | 36,23 | 243.177 | 8.810.303 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 14.08.2026 | Optionsausübung | 3,85 | 243.177 | 936.231 | Form 4 |
| ROIV | Venker Eric | President & Immunovant CEO | 27.07.2026 | Verkauf | 34,95 | 200.000 | 6.990.000 | Form 4 |
| ROIV | Venker Eric | President & Immunovant CEO | 27.07.2026 | Optionsausübung | 3,85 | 200.000 | 770.000 | Form 4 |
| ROIV | Momtazee James C | Director | 17.07.2026 | Zuteilung | — | 405 | — | Form 4 |
| ROIV | Epperly Melissa B, | Director | 17.07.2026 | Zuteilung | — | 543 | — | Form 4 |
| ROIV | Oren Ilan | Director | 17.07.2026 | Zuteilung | — | 775 | — | Form 4 |
| ROIV | Eric Venker | CEO | 20.04.2026 | Verkauf | 29,59 | 200.000 | 5.918.000 | Form 4 |
Kompakter Markt-Überblick — keine Anlageberatung. Quelle: Fundamentaldaten & SEC-Berichte (Geschäfts- und Quartalsberichte, 10-K/10-Q).